Tesaro Inc. is a pharmaceutical company based in

Waltham, Massachusetts Waltham ( ) is a city in Middlesex County, Massachusetts, United States, and was an early center for the labor movement as well as a major contributor to the American Industrial Revolution. The original home of the Boston Manufacturing Company, th ...

. They focus on drug development for

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

History

Tesaro was founded in 2010. The company's first commercial product,

Varubi Rolapitant (INN, trade name Varubi in the US and Varuby in the European Union) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK1 receptor antagonist ( antagonist for ...

, was approved by the

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale. On December 3, 2018, GSK announced it would acquire the company for $5.1 billion, and the deal was completed on January 22, 2019.

Products under development

Rolapitant Rolapitant (INN, trade name Varubi in the US and Varuby in the European Union) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK1 receptor antagonist (antagonist for ...

– intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting *

Niraparib Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken Oral administration, by mouth. It is a PARP inhibitor. The most co ...

– PARP inhibitor in clinical trials for breast and ovarian cancer. * TSR-042 * TSR-022

References

External links

* {{Authority control Pharmaceutical companies of the United States Health care companies based in Massachusetts Companies based in Waltham, Massachusetts Pharmaceutical companies established in 2010 2010 establishments in Massachusetts 2012 initial public offerings 2019 mergers and acquisitions Companies formerly listed on the Nasdaq American subsidiaries of foreign companies GSK plc